Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3) (eREACH3)

The purpose of the study is to understand patient interest in telehealth and digital tools for pre-test genetic education and/or disclosure of genetic test results. Participants will receive telehealth genetic counseling in the home and may be offered various digital tools to help with the counseling and testing process. These are optional and participants can still speak with a genetic counselor if they wish.

Study Overview

• Status: Recruiting
• Conditions: Cancer

Detailed Description

The goal of the eREACH3 Study is to evaluate the implementation of these tools into remote genetic services, evaluating uptake and use of digital tools and outcomes in representative clinical populations. The initial protocol will include two genetic counseling visits, providing comparison outcomes. Future amendments will be provided as digital tools are ready for implementation.

Specific Aim 1: (Reach) Evaluate the uptake, use and acceptability of digital delivery alternatives in remote genetic services provided as alternatives to the traditional two-visit model with a genetic counselor.

Specific Aim 2: (Effectiveness) Evaluate short-term and 6 month patient reported cognitive, affective and behavioral outcomes (2a) with remote genetic services and digital alternatives in representative clinical populations and moderators of outcomes (2b).

Specific Aim 3: (Implementation) Evaluate provider time associated with implementation of remote telehealth services and digital delivery alternatives and barriers and facilitators to future clinical implementation.

• Study Type: Observational
• Enrollment (Estimated): 360

Contacts and Locations

• Study Contact: Name: Kelsey Karpink; Phone Number: 215-662-3531; Email: kelsey.karpink@pennmedicine.upenn.edu
• Study Contact Backup: Name: Angela Bradbury, MD; Phone Number: 215-615-3341; Email: angela.bradbury@pennmedicine.upenn.edu

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Recruiting
      • Abramson Cancer Center at the University of Pennsylvania
      • Contact: Angela Bradbury, MD; Phone Number: 215-615-3341; Email: angela.bradbury@pennmedicine.upenn.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Individuals with personal or family history of cancer.

Description

Inclusion Criteria:

• 18 years of age or older
• Speak and understand English
• Meet current National Comprehensive Cancer Network (NCCN) or other national guidelines for germline genetic testing or are interested in genetic counseling based on personal or family history of cancer. Patients with prior genetic testing are eligible if they meet criteria for updated testing, or if post-test genetic counseling services are requested.

Exclusion Criteria:

• Communication difficulties such as:
• Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded.
• Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.
• Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Visit 1; All participants will be offered remote telehealth Visit 1 services by telephone or real-time videoconference or by a chatbot (patient choice).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Uptake of Visit 1	Participant completion of Visit 1 (yes/no)	Through 6 months
Uptake of Digital Visit 1	Participant completion of digital intervention as an alternative for Visit 1 (yes/no)	Through 6 months
Uptake of genetic testing	Participant completion of genetic testing and received results/Visit 2 (yes/no)	Through 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The KnowGene Scale	Change in Knowledge - Score Range = 0-16, Higher score = Better outcome	Through study completion, an average of 6 months
Test result recall	Recall of genetic testing results	Through study completion, an average of 6 months
Impact of Events Scale (IES)	Change in Cancer Specific Distress - Score Range = 0-40, Lower score = Better outcome	Through study completion, an average of 6 months
Satisfaction with genetic services	Differences in satisfaction - Score Range = 14-70, Higher score = Better outcome	Through study completion, an average of 6 months
Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)	Change in Uncertainty - Score Range = 0-85, Lower score = Better outcome	Through study completion, an average of 6 months
Decisional Regret Scale	Differences in decisional regret - Score Range = 5-25, Lower score = Better outcome	Through study completion, an average of 6 months

Collaborators and Investigators

• Sponsor: Abramson Cancer Center at Penn Medicine
• Collaborators: Fox Chase Cancer Center
• Investigators: Principal Investigator: Angela Bradbury, MD, University of Pennsylvania

Study record dates

Study Major Dates

• Study Start (Actual): September 2, 2025
• Primary Completion (Estimated): March 1, 2029
• Study Completion (Estimated): March 1, 2029

Study Registration Dates

• First Submitted: November 13, 2025
• First Submitted That Met QC Criteria: March 12, 2026
• First Posted (Actual): March 13, 2026

Study Record Updates

• Last Update Posted (Actual): March 13, 2026
• Last Update Submitted That Met QC Criteria: March 12, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: UPCC 12025; IRB#858825 (Other Identifier: University of Pennsylvania IRB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No